You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
Merck
Boehringer Ingelheim
Johnson and Johnson
Harvard Business School

Last Updated: April 12, 2021

DrugPatentWatch Database Preview

Lannett Co Inc Company Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for LANNETT CO INC, and when can generic versions of LANNETT CO INC drugs launch?

LANNETT CO INC has one hundred and thirty-nine approved drugs.

There is one US patent protecting LANNETT CO INC drugs. There is one tentative approval on LANNETT CO INC drugs.

There are fifteen patent family members on LANNETT CO INC drugs in twelve countries and one hundred and twenty supplementary protection certificates in twelve countries.

Summary for Lannett Co Inc
International Patents:15
US Patents:1
Tradenames:104
Ingredients:97
NDAs:139
Drug Master File Entries: 1

Drugs and US Patents for Lannett Co Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lannett Co Inc OXYBUTYNIN CHLORIDE oxybutynin chloride SYRUP;ORAL 076682-001 Dec 28, 2004 DISCN No No   Start Trial   Start Trial
Lannett Co Inc LETROZOLE letrozole TABLET;ORAL 202048-001 Oct 29, 2014 DISCN No No   Start Trial   Start Trial
Lannett Co Inc BETHANECHOL CHLORIDE bethanechol chloride TABLET;ORAL 040677-003 Mar 27, 2008 AA RX No No   Start Trial   Start Trial
Lannett Co Inc METHYLPHENIDATE HYDROCHLORIDE methylphenidate hydrochloride TABLET, EXTENDED RELEASE;ORAL 091695-002 Jul 9, 2013 BX RX No No   Start Trial   Start Trial
Lannett Co Inc ATORVASTATIN CALCIUM atorvastatin calcium TABLET;ORAL 091624-002 Apr 5, 2013 AB RX No No   Start Trial   Start Trial
Lannett Co Inc MORPHINE SULFATE morphine sulfate SOLUTION;ORAL 202309-001 Nov 25, 2015 DISCN No No   Start Trial   Start Trial
Lannett Co Inc BACLOFEN baclofen TABLET;ORAL 077241-002 Jul 6, 2007 AB RX No No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Lannett Co Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lannett Co Inc METADATE CD methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021259-002 Jun 19, 2003 6,344,215   Start Trial
Lannett Co Inc METADATE CD methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021259-003 May 27, 2003 6,344,215   Start Trial
Lannett Co Inc MYKROX metolazone TABLET;ORAL 019532-001 Oct 30, 1987 4,517,179   Start Trial
Lannett Co Inc METADATE CD methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021259-001 Apr 3, 2001 6,344,215   Start Trial
Lannett Co Inc METADATE CD methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021259-004 Feb 19, 2006 6,344,215   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for LANNETT CO INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Delayed-release Tablets 20 mg ➤ Subscribe 2015-06-03
➤ Subscribe Extended-release Capsules 40 mg ➤ Subscribe 2007-03-15
➤ Subscribe Extended-release Capsules 10 mg, 20 mg and 30 mg ➤ Subscribe 2005-05-13

Supplementary Protection Certificates for Lannett Co Inc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1389098 300609 Netherlands   Start Trial PRODUCT NAME: LOXAPINE; REGISTRATION NO/DATE: EU/1/13/823/001-002 20130220
1411900 2011/016 Ireland   Start Trial PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE MODIFIED-RELEASE TABLETS; NAT REGISTRATION NO/DATE: PA0970/060/001 20101221; FIRST REGISTRATION NO/DATE: PL17901/0263-0001 20101105
1441735 2008/010 Ireland   Start Trial PRODUCT NAME: RALTEGRAVIR OR A PHARMECEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT; NAT AUTHORISTION NO/DATE: EU/1/07/436/001-002 20071220;
0247633 97C0103 Belgium   Start Trial PRODUCT NAME: CALCII ATORVASTATINUM TRIHYDRICUM (=ATORVASTATINUM); NAT. REGISTRATION NO/DATE: 19 IS 95 F 3 19970922; FIRST REGISTRATION: GB PL/00018/0240 19961107
1685839 92292 Luxembourg   Start Trial PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE
0367141 SPC/GB04/039 United Kingdom   Start Trial PRODUCT NAME: ARIPIPRAZOLE OR A SALT THEREOF; REGISTERED: UK EU/1/04/276/001 20040604; UK EU/1/04/276/002 20040604; UK EU/1/04/276/003 20040604; UK EU/1/04/276/004 20040604; UK EU/1/04/276/005 20040604; UK EU/1/04/276/006 20040604; UK EU/1/04/276/007 20040604; UK EU/1/04/276/008 20040604; UK EU/1/04/276/009 20040604; UK EU/1/04/276/010 20040604; UK EU/1/04/276/011 20040604; UK EU/1/04/276/012 20040604; UK EU/1/04/276/013 20040604; UK EU/1/04/276/014 20040604; UK EU/1/04/276/015 20040604; UK EU/1/04/276/016 20040604; UK EU/1/04/276/017 20040604; UK EU/1/04/276/018 20040604; UK EU/1/04/276/019 20040604; UK EU/1/04/276/020 20040604
1507558 12C0033 France   Start Trial PRODUCT NAME: ALISKIRENE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE E CELUI-CI, AMLODIPINE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, ET HYDROCHLOROTHIAZIDE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; NAT. REGISTRATION NO/DATE: EU/1/11/730/001 20111122; FIRST REGISTRATION: 6167801 20110705
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
Dow
Express Scripts
McKinsey
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.